Physicians' concerns about the Marshall Protocol

anonymous@undisclosed.example.com (Anonymous) — Wed, 14 Sep 2022 20:53:47 +0000

Notice for emergency medical personnel

anonymous@undisclosed.example.com (Anonymous) — Wed, 14 Sep 2022 20:53:47 +0000

11.21.2018		current
Line 36:		Line 36:


-	These antibiotics usually cause either an allergic reaction or a cytokine storm:	+	The listed antibiotics may cause either an allergic reaction or a cytokine storm:
	* azithromycin (note especially cardiovascular sequelae)		* azithromycin (note especially cardiovascular sequelae)
	* clindamycin (note especially neurological sequelae)		* clindamycin (note especially neurological sequelae)
Line 74:		Line 74:


		+	<nodisp>
	===== Notes and comments =====		===== Notes and comments =====

Line 81:		Line 82:
	<html>		<html>
	<!--<form>		<!--<form>
-	<a href="http://AutoimmunityResearch.org/ER.pdf"><input type="image" name="Submit" value="Download as PDF" src="http://mpkb.org/_media/home/downloadpdf.gif"; class="buttoncalc hide" /></a>	+	<a href="https://AutoimmunityResearch.org/ER.pdf"><input type="image" name="Submit" value="Download as PDF" src="https://mpkb.org/_media/home/downloadpdf.gif"; class="buttoncalc hide" /></a>
	</form>-->		</form>-->


-	<a href="http://AutoimmunityResearch.org/ER.pdf"><img src="http://mpkb.org/_media/home/downloadpdf.gif" class="pdfbutton" /></a>	+	<a href="https://AutoimmunityResearch.org/ER.pdf"><img src="https://mpkb.org/_media/home/downloadpdf.gif" class="pdfbutton" /></a>


-	</html>	+	</html></nodisp>

Testing Vitamin D Metabolites

anonymous@undisclosed.example.com (Anonymous) — Wed, 14 Sep 2022 05:14:49 +0000

07.13.2019		current
Line 10:		Line 10:
	* a [[home:publications:proal_molecular_2011\|2011 case series of MP patients]] appearing in the (Nature Publishing Group) journal //Clinical & molecular immunology//		* a [[home:publications:proal_molecular_2011\|2011 case series of MP patients]] appearing in the (Nature Publishing Group) journal //Clinical & molecular immunology//
	* a [[home:publications:mp2008_survey\|2008 retrospective survey]] of 100 MP patients with autoimmune diagnoses		* a [[home:publications:mp2008_survey\|2008 retrospective survey]] of 100 MP patients with autoimmune diagnoses
-	* anecdotal physician and patient reports on [[http://MarshallProtocol.com\|MarshallProtocol.com]], [[https://www.marshallprotocol.com/category8/\|MEMBERS PROGRESS]]. Medical personnel need to log in to view those forums. (there are also about [[http://bacteriality.com/category/interview-patient/\|20 patient interviews]] on the site Bacteriality.com)	+	* anecdotal physician and patient reports on [[https://MarshallProtocol.com\|MarshallProtocol.com]], [[https://www.marshallprotocol.com/category8/\|MEMBERS PROGRESS]]. Medical personnel need to log in to view those forums. (there are also about [[https://bacteriality.com/category/interview-patient/\|20 patient interviews]] on the site Bacteriality.com)
	* evidence that an immunostimulatory approach may be useful in chronic inflammatory diseases including, for example, [[home:pathogenesis:evidence_bacteria\|reports of infection]] in these conditions		* evidence that an immunostimulatory approach may be useful in chronic inflammatory diseases including, for example, [[home:pathogenesis:evidence_bacteria\|reports of infection]] in these conditions
	* evidence of Olmesartan having [[home:protocol:olmesartan#Cardiovascular disease\|beneficial effects]] on Cardiovascular function and [[home:protocol:olmesartan#kidney_disease\|kidney disease]]		* evidence of Olmesartan having [[home:protocol:olmesartan#Cardiovascular disease\|beneficial effects]] on Cardiovascular function and [[home:protocol:olmesartan#kidney_disease\|kidney disease]]
Line 17:		Line 17:

	For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment:		For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment:
-	* alternative hypotheses and evidence of research (({{pubmed>long: 15246025}})), (({{pubmed>long:16403216}})), (({{pubmed>long:23370376}})), (({{pubmed>long:18200565}}))	+	* alternative hypotheses and evidence of research (({{pmid>long: 15246025}})), (({{pmid>long:16403216}})), (({{pmid>long:23370376}})), (({{pmid>long:18200565}}))
	* evidence for the efficacy of MP versus other available treatment in 2013 data on patient response, see section below		* evidence for the efficacy of MP versus other available treatment in 2013 data on patient response, see section below
-	* patients' expressed preferences and values(({{pubmed>long:19050187}}))	+	* patients' expressed preferences and values(({{pmid>long:19050187}}))
	* additional benefits of Olmesartan [[https://mpkb.org/home/protocol/olmesartan#other_benefits_of_olmesartan_in_patients_-_recent_studies\|other researched benefits]]		* additional benefits of Olmesartan [[https://mpkb.org/home/protocol/olmesartan#other_benefits_of_olmesartan_in_patients_-_recent_studies\|other researched benefits]]
	* orphan drug status – Autoimmunity Research Foundation has won [[home:publications:applications_orphan_status\|orphan drug status]] from the FDA for several medications and indications, and is committed to working further with the agency to get the MP approved for a broader range of indications.		* orphan drug status – Autoimmunity Research Foundation has won [[home:publications:applications_orphan_status\|orphan drug status]] from the FDA for several medications and indications, and is committed to working further with the agency to get the MP approved for a broader range of indications.
Line 82:		Line 82:
	- "A temporary increase in symptoms or laboratory values means the treatment is not working." – \\ Immunopathology is an increase in one's present symptoms of Th1 inflammation or a return of previous Th1 inflammatory symptoms, that is caused by cytokines and endotoxins being released from dying bacteria. In some cases there may be a temporary experience of symptoms attributable to a previously unexperienced condition. Immunopathology is a necessary part of recovery. The amount of immunopathology a patient experiences on the Marshall Protocol (MP) is correlated with disease severity. Patients who are less sick will have comparatively less strong immunopathology. [[home:protocol:immunopathology\|Read more →]]		- "A temporary increase in symptoms or laboratory values means the treatment is not working." – \\ Immunopathology is an increase in one's present symptoms of Th1 inflammation or a return of previous Th1 inflammatory symptoms, that is caused by cytokines and endotoxins being released from dying bacteria. In some cases there may be a temporary experience of symptoms attributable to a previously unexperienced condition. Immunopathology is a necessary part of recovery. The amount of immunopathology a patient experiences on the Marshall Protocol (MP) is correlated with disease severity. Patients who are less sick will have comparatively less strong immunopathology. [[home:protocol:immunopathology\|Read more →]]

-	see also [[home:protocol:olmesartan:safety\|https://mpkb.org/home/protocol/olmesartan/safety#recent_research\|research into enteropathy]]	+	see also [[home:protocol:olmesartan:safety#recent_research\|research into Enteropathy]]

	===== Concerns about antibiotics=====		===== Concerns about antibiotics=====
Line 109:		Line 109:
	==== Read also ====		==== Read also ====

-	[[http://electromagnetichealth.org/wp-content/uploads/2012/04/EMF-Guideline.pdf\|Guideline of the Austrian Medical Association for the diagnosis and treatment of EMF-related health problems and illnesses (EMF syndrome) ]]	+	[[https://electromagnetichealth.org/wp-content/uploads/2012/04/EMF-Guideline.pdf\|Guideline of the Austrian Medical Association for the diagnosis and treatment of EMF-related health problems and illnesses (EMF syndrome) ]]

-	Evaluation of the Effect of Radiofrequency Radiation Emitted From Wi-Fi Router and Mobile Phone Simulator on the Antibacterial Susceptibility of Pathogenic Bacteria Listeria monocytogenes and Escherichia coli.\\ Altogether, the findings of this study showed that exposure to Wi-Fi and RF simulator radiation can significantly alter the inhibition zone diameters and growth rate for L monocytogenes and E coli. These findings may have implications for the management of serious infectious diseases. (({{pubmed>long:28203122}}))	+	Evaluation of the Effect of Radiofrequency Radiation Emitted From Wi-Fi Router and Mobile Phone Simulator on the Antibacterial Susceptibility of Pathogenic Bacteria Listeria monocytogenes and Escherichia coli.\\ Altogether, the findings of this study showed that exposure to Wi-Fi and RF simulator radiation can significantly alter the inhibition zone diameters and growth rate for L monocytogenes and E coli. These findings may have implications for the management of serious infectious diseases. (({{pmid>long:28203122}}))
	<blockquote>Previous studies have shown that exposure of microorganisms to RF-EMFs can be associated with a wide spectrum of changes ranged from the modified bacterial growth to the alterations of the pattern of antibiotic resistance.		<blockquote>Previous studies have shown that exposure of microorganisms to RF-EMFs can be associated with a wide spectrum of changes ranged from the modified bacterial growth to the alterations of the pattern of antibiotic resistance.

Line 120:		Line 120:

	[[home:starting:physician:reluctant#Specific_research\|Section to print off - Independent research into Olmesartan with PMIDs for doctor.]]		[[home:starting:physician:reluctant#Specific_research\|Section to print off - Independent research into Olmesartan with PMIDs for doctor.]]
		+	<nodisp>
	===== Notes and comments =====		===== Notes and comments =====

Line 130:		Line 131:
	* CureMyTh1.org references removed during transition to closing that site. --- //Joyful 01.04.2014//		* CureMyTh1.org references removed during transition to closing that site. --- //Joyful 01.04.2014//

-	===== References =====	+	===== References =====</nodisp>

02.10.2019		current
Line 1:		Line 1:

-	====== Testing Your Vitamin D Metabolites ======	+	====== Testing Vitamin D Metabolites ======

	===== Inflammatory Markers Of Chronic Disease =====		===== Inflammatory Markers Of Chronic Disease =====
Line 19:		Line 19:
	density and calcification risk.		density and calcification risk.

-	see also Clinical Utility of Measurement of Vitamin D-Binding Protein and Calculation of Bioavailable Vitamin D in Assessment of Vitamin D Status (({{pubmed>long:27834063}}))	+	see also Clinical Utility of Measurement of Vitamin D-Binding Protein and Calculation of Bioavailable Vitamin D in Assessment of Vitamin D Status (({{pmid>long:27834063}}))

	==== Metabolism and Immunostimulation ====		==== Metabolism and Immunostimulation ====
Line 122:		Line 122:
	1. Marshall TG: Vitamin D discovery outpaces FDA decision making.		1. Marshall TG: Vitamin D discovery outpaces FDA decision making.
	BioEssays. 2008 Feb;30(2):173-82 Online ISSN: 1521-1878 Print ISSN: 0265-9247 Preprint of FullText available from URL		BioEssays. 2008 Feb;30(2):173-82 Online ISSN: 1521-1878 Print ISSN: 0265-9247 Preprint of FullText available from URL
-	http://TrevorMarshall.com/BioEssays-Feb08-Marshall-Preprint.pdf	+	https://TrevorMarshall.com/BioEssays-Feb08-Marshall-Preprint.pdf

	2. Proal AD, Albert PJ, Marshall TG: Dysregulation of the Vitamin D Nuclear		2. Proal AD, Albert PJ, Marshall TG: Dysregulation of the Vitamin D Nuclear
Line 132:		Line 132:
	3. Albert PJ, Proal AD, Marshall TG: Vitamin D: the alternative hypothesis.		3. Albert PJ, Proal AD, Marshall TG: Vitamin D: the alternative hypothesis.
	Autoimmunity Reviews. 2009 Jul;8(8):677-81.Preprint available from		Autoimmunity Reviews. 2009 Jul;8(8):677-81.Preprint available from
-	http://AutoimmunityResearch.org/transcripts/AR-Albert-VitD.pdf	+	https://AutoimmunityResearch.org/transcripts/AR-Albert-VitD.pdf

	4. Proal AD, Albert PJ, Marshall TG: Autoimmune disease in the era of the		4. Proal AD, Albert PJ, Marshall TG: Autoimmune disease in the era of the
	Metagenome. Autoimmunity Reviews. 2009 Jul;8(8):639-44.		Metagenome. Autoimmunity Reviews. 2009 Jul;8(8):639-44.
-	http://AutoimmunityResearch.org/transcripts/AR-Proal-Metagenome.pdf	+	https://AutoimmunityResearch.org/transcripts/AR-Proal-Metagenome.pdf

	5. Proal AD, Albert PJ, Marshall TG: Infection, Autoimmunity, and Vitamin		5. Proal AD, Albert PJ, Marshall TG: Infection, Autoimmunity, and Vitamin

Marshall Protocol Knowledge Base - home:physicians

Physicians' concerns about the Marshall Protocol

Notice for emergency medical personnel

Testing Vitamin D Metabolites